Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Q2 2022 Earnings Presentation
24 slides from Lytix Biopharma ASA's earnings presentation, Aug 25, 2022
Slide 1: New encouraging clinical data – Second quarter 2022 presentation
Lytix Biopharma AS New encouraging clinical data Second quarter 2022 presentation August 25, 2022
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Today's presenters
Today's presenters Øystein Rekdal / CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s oncolytic molecule platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof
Slide 4: Lytix Biopharma in brief
Lytix Biopharma in brief • Lytix is a clinical stage biotech company headquartered in Oslo, Norway • The company was listed at Euronext Growth in June 2021 • Lytix has developed a unique and proprietary technology platform for cancer treatment • Lytix aims to accelerate progression of this unique pl
Slide 5: Highlights of the second quarter 2022
Highlights of the second quarter 2022 In April, Verrica Pharmaceuticals dosed the first patient in their Phase II study evaluating LTX-315 in basal cell carcinoma, triggering a milestone payment to Lytix of USD 1 million. The results from the ATLAS-IT-04 study presented at ASCO in June demonstrated
Slide 6: Clinical/operational update
Clinical/operational update
Slide 7: Licence partner Verrica shows progress with Phase II study in basal cell carcinoma
Lytix` license partner Verrica shows progress with their Phase II study in basal cell carcinoma First patient in Verrica`s Phase II study was dosed on April 4th This triggered a milestone payment of USD 1 million to Lytix Approximately 66 patients with Basal Cell Carcinoma will be enrolled in the st
Slide 8: ATLAS-IT-04: Rationale for combining LTX-315 with Adoptive Cell Therapy
ATLAS-IT-04: Rational for combining LTX-315 with Adoptive Cell Therapy ACT therapy ‒ T cells are isolated and multiplied before being transferred back to the cancer patient ACT therapy has shown promising effects in melanoma In sarcoma and many other tumor types ACT will not be effective as a stand-
Slide 9: ATLAS-IT-04: LTX-315 combined with Adoptive Cell Therapy
ATLAS-IT-04: LTX-315 combined with Adoptive Cell Therapy LTX-315 in combination with ACT stabilized the disease in patients with progressive metastatic soft tissue sarcoma for up to 26 weeks (N=6) LTX-315 generated T cells that were able to recognize tumor-specific antigens enabling the immune syste
Slide 10: ATLAS-IT-05: Phase II study with lead candidate LTX-315
ATLAS-IT-05: Phase II study with our lead cancer drug candidate LTX-315 A Phase II combination study evaluating LTX-315 and pembrolizumab in patients with solid tumors Objective for the study ‒ Document whether LTX-315 in combination with pembrolizumab is effective in inducing responses in patients
Slide 11: ATLAS-IT-05: Factors to drive enrollment
ATLAS-IT-05: Factors to drive enrollment Current status ‒ Sites in the US are open and recruitment ongoing COVID-19 continues to impact site resources ‒ To mitigate recruitment challenges, the study is expanding to sites in Europe ‒ The regulatory application in Europe was submitted in Q2 2022 and s
Slide 12: LTX-401: Lytix' second generation oncolytic molecule
LTX-401: Lytix` second generation oncolytic molecule LTX-401 has demonstrated a commercial potential for deep-seated tumors such as hepatocellular carcinoma and other cancer types that spread to the liver. Liver cancers represent big cancer segments with high unmet medical need and significant marke
Slide 13: Pipeline
Pipeline Product Combination Population Preclinical Phase I Phase II Phase III Collaborators candidate partner ATLAS-IT-05 Patients progressed Pembroluzimab on checkpoint MD Anderson (logo) (Keytruda®) inhibitors Verrica Basal cell Verrica Pharmaceuticals LTX-315 Pharmaceuticals carcinoma (logo) Mon
Slide 14: Key company objectives for 2022
Key company objectives for 2022 Expand the clinical impact field for LTX-315 and drive enrollment in the ATLAS-IT-05 Phase II trial towards completion Support our commercial partner Verrica Pharmaceuticals in their Phase II trial in BCC Initiate discussion with partners with commercial interest in A
Slide 15: Key figures
Key figures
Slide 16: Key figures – profit and loss
Key figures – profit and loss Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 Total operating income 10,427 1,640 11,936 23,201 25,827 Total operating expenses (20,418) (14,041) (36,600) (36,054) (73,844) Loss from operations (9,991) (12,401)
Slide 17: Key figures – balance sheet
Key figures – balance sheet Unaudited Unaudited Amounts in NOK thousands 30.06.2022 30.06.2021 31.12.2021 Assets Property, plant and equipment 132 - - Trade and other receivables 6,893 162,792 5,680 Cash and cash equivalents 177,084 70,950 197,282 Total assets 184,108 233,742 202,962 Shareholder's e
Slide 18: Summary
Summary
Slide 19: Why we will succeed
Why we will succeed UNIQUE APPROACH SCIENCE VALIDATION EXECUTION Lytix’s molecules Science confirmed by Commercial deal within Management represent the missing top notch US and skin cancer Board piece European cancer research institutions US health specialist Completed Phase II Ideal combination fun
Slide 20: Interim Financial Statements
Interim Financial Statements
Slide 21: Interim statement of profit or loss
Interim statement of profit or loss Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 Revenue - - - 17 17 Other operating income 10,427 1,640 11,936 23,184 25,810 Total operating income 10,427 1,640 11,936 23,201 25,827 Payroll and related expen
Slide 22: Interim statement of financial position
Interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 30.06.2022 30.06.2021 31.12.2021 Assets Non-current assets Property, plant and equipment 132 - - Total non-current assets 132 - - Current assets Trade and other receivables 6,893 162,792 5,680 Cash and cash equivale
Slide 23: Interim statement of cash flows
Interim statement of cash flows Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q2 2022 Q2 2021 H1 2022 H1 2021 FY 2021 Cash flows from operating activities Loss for the period (1,183) (12,392) (16,414) (12,742) (48,049) Adjustments for: Depreciation of property, plant and equipment
Slide 24: Q&A
Q&A IR enquiries: ole.peter.nordby@lytixbiopharma.com